Nora
Nora Alonso Casajus, Pamplona ES
Patent application number | Description | Published |
---|---|---|
20090288219 | Method of Production of Recombinant Sucrose Synthase, Use Thereof in the Manufacture of Kits for Determination of Sucrose, Production of Adpglucose and Production of Transgenic Plants Whose Leaves and Storage Organs Accumulate High Contents of Adpglucose and Starch - Method of production of recombinant sucrose synthase, use thereof in the manufacture of kits for determination of sucrose, production of ADPglucose and production of transgenic plants whose leaves and storage organs accumulate high contents of ADPglucose and starch | 11-19-2009 |
Nora Alonso Casajus US
Patent application number | Description | Published |
---|---|---|
20130007928 | METHOD OF PRODUCTION OF RECOMBINANT SUCROSE SYNTHASE, USE THEREOF IN THE MANUFACTURE OF KITS FOR DETERMINATION OF SUCROSE, PRODUCTION OF ADPGLUCOSE AND PRODUCTION OF TRANSGENIC PLANTS WHOSE LEAVES AND STORAGE ORGANS ACCUMULATE HIGH CONTENTS OF ADPGLUCOSE AND STARCH - A transgenic plant that overexpresses sucrose synthase. The transgenic plant has a genetic construct that encodes a sucrose synthase peptide. | 01-03-2013 |
Nora Alonso Casajús, Pamplona ES
Patent application number | Description | Published |
---|---|---|
20110271401 | PROCEDURE FOR PRODUCING TRANSGENIC PLANTS PROVIDING HIGH STARCH CONTENT AND YIELD AND HIGH AMYLOSE/AMYLOPECTIN BALANCE - A process for the production of transgenic plants that have a high starch content and yield and a high amylose/amylopectin ratio. The alpha-1,4-glucan phosphorylases (GPs) catalyze the reversible cutting of bonds α-1,4 of the non-reducing ends of homopolysaccharides with at least 5 glucose molecules such as starch, maltodextrin and glycogen, leading to production of glucose-1-phosphate. The GPs in bacteria and animal cells are responsible for the breakdown of glycogen. Although the increase in GP activity leads to a reduction in intracellular levels of glycogen in bacteria and animal cells, this invention discloses the production of plants that have high starch levels and yields and high amylose/amylopectin ratio, as result of the expression of genes coding for GPs. | 11-03-2011 |
Nora Bayani, Berkeley, CA US
Patent application number | Description | Published |
---|---|---|
20130331405 | PIK3CA Mutation Status and SASH1 Expression Predicts Synergy Between Lapatinib and an AKT Inhibitor in HER2 Positive Breast Cancer - Methods for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib, and an AKT inhibitor, comprising detecting modulated expression of HER2 (ERBB2) and SASH1 or protein encoded thereof and detecting PIK3CA mutation status. High levels of expression in HER2 and high levels of SASH1 and/or positive PIK3CA mutation status indicate a patient that is suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib and an AKT inhibitor. | 12-12-2013 |
Nora Benhabiles, Paris FR
Patent application number | Description | Published |
---|---|---|
20110053167 | GENE SIGNATURES - The present invention relates generally to a new cluster of correlating molecules in a tissue or at least one cell of a tissue for instance a cell of a blood tissue, preferably such myeloid cells and of identifying the condition of the genes expression said correlating molecules or of the expression levels of said molecules in a method or system for identifying obesity and the risk at obesity-related metabolic diseases such as the obesity associated cardiovascular risk or obesity-related insulin resistance. This system of method provides information on how to modulate the correlating molecules to treat or prevent obesity and to prevent the obesity-related metabolic diseases. | 03-03-2011 |
Nora Berois, Montevideo UY
Patent application number | Description | Published |
---|---|---|
20150241432 | NOVEL METHOD TO DETECT RESISTANCE TO CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER - The invention is directed to processes, assays and methods for determining the likelihood of chemotherapy resistance and predicting response to chemotherapy in a subject with cancer. In an embodiment, the subject has lung cancer. | 08-27-2015 |
Nora Dabbous, Suresnes FR
Patent application number | Description | Published |
---|---|---|
20090172268 | METHOD FOR SECURING A MICROPROCESSOR, CORRESPONDING COMPUTER PROGRAM AND DEVICE - A method is provided for securing a microprocessor containing at least one main program, which operates with at least one memory. The method includes implementing counter-measures, during which additional operations, that are not required for the main program, are implemented so as to modify the consumption of current and/or the processing time of the microprocessor. The method also includes: identification of at least one address or one memory zone of the memory(ies), called critical addresses, and which contain, or which may contain, critical data for said main program; monitoring the addressing ports of the memory(ies), so as to detect the access to the critical address(es); and activation of the step of implementing counter-measures, when an access to the critical address(es) is detected. | 07-02-2009 |
20150278792 | Method for verifying the authenticity of a terminal, corresponding device and program - A method is provided for verifying an authenticity of a payment terminal, implemented by using of a device for verifying authenticity. The method includes: transmitting to the payment terminal a request for obtaining a piece of identification data by using of a contactless communications interface; receiving a response, through said contactless communications interface and coming from the payment terminal, to said request for obtaining a piece of identification data; comparing a field of said response with at least one piece of pre-recorded identification data; when the field includes a piece of identification data identical to said at least one piece of pre-recorded identification data, for issuing an assertion of authenticity of said payment terminal; when the field comprises a piece of identification data different from said at least one piece of pre-recorded identification data, issuing a piece of information on absence of authentication of the payment terminal. | 10-01-2015 |
20160048706 | METHOD AND DEVICE FOR SECURE VIEWING ON A SCREEN OF AN ELECTRONIC TERMINAL, AND CORRESPONDING TERMINAL - A method for secure viewing on a screen of an electronic terminal includes determining a mode of operation, secured or open, of the terminal; and modifying the displaying of at least one indicator representing the mode of operation of the terminal. The displaying modification is controlled by at least one secure processor of the terminal and takes into account at least one predetermined action of the user on the terminal and/or of an expiration of at least one predetermined time limit. | 02-18-2016 |
Nora Duhanyan, Nolsy-Le-Grand FR
Patent application number | Description | Published |
---|---|---|
20090000390 | Method and Apparatus for Measuring the Flow Rates of the Individual Phases of a Multiphase Fluid Mixture - A flow rate measuring method for a multiphase fluid mixture FM flowing into a line LN, the fluid mixture FM comprising at least a first and a second phase, the method comprising the steps of: passing the fluid mixture through a Venturi tube in which the fluid mixture is subjected to a pressure drop, continuously measuring by means of said Venturi tube permanently installed on the line a differential pressure across the Venturi tube ΔP | 01-01-2009 |
Nora Gourdoupi, Patras GR
Patent application number | Description | Published |
---|---|---|
20080233455 | Proton conductors based on aromatic polyethers and their use as electolytes in high temperature pem fuel cells - Polymer electrolyte membranes with polyethylene oxide and phophonic acid moieties tethered on the main polyether backbone are provided as single phase proton conductors. Preferred polymers can exhibit good mechanical properties, high thermal and oxidative stability. The membrane-electrode assembly (MEA) is also provided. | 09-25-2008 |
20080248364 | Proton conducting aromatic polyether type copolymers bearing main and side chain pyridine groups for use in proton exchange membrane fuel cells - New aromatic polyether type copolymers bearing main chain pyridine and side chain pyridine or pyrimidine units, which exhibit good mechanical properties, high thermal and oxidative stability, high doping ability and high conductivity values. The polymers are useful in the preparation and application of MEA on PEMFC type single cells. The polymers are, further, particularly suitable for use in high temperature PEM fuel cells. | 10-09-2008 |
20090081487 | Acid-Doped Polyelectrolyte Modified Carbon Nanotubes and their Use in High Temperature PEM Fuel Cell Electrodes - New multifunctional aromatic copolymers bearing pyridine or pyrimidine units either in the main chain or side chain and single wall carbon nanotubes or multi wall carbon nanotubes as side chain pendants have been prepared. These multifunctional materials will combine both high proton and electrical conductivity due to the existence of polar pyridine or pyrimidine groups and carbon nanotubes within the same chemical structure. The prepared multifunctional materials can be used in the catalyst ink of the electrodes in high temperature PEM fuel cells. | 03-26-2009 |
20100047660 | DEVELOPMENT AND CHARACTERIZATION OF NOVEL PROTON CONDUCTING AROMATIC POLYETHER TYPE COPOLYMERS BEARING MAIN AND SIDE CHAIN PYRIDINE GROUPS - Featured are novel heterocycle substituted hydroquinones, aromatic copolymers and homopolymers bearing main and side chain polar pyridine units. These polymers exhibit good mechanical properties, high thermal and oxidative stability, high doping ability and high conductivity values. These novel polymers can be used in the preparation and application of MEA on PEMFC type single cells. The combination of the above mentioned properties indicate the potential of the newly prepared materials to be used as electrolytes in high temperature PEM fuel cells. | 02-25-2010 |
20120086385 | FUEL PROCESSOR/FUEL CELL SYSTEM FOR PROVIDING POWER TO REFRIGERATORS AT OUT-OF-GRID LOCATIONS, AND A METHOD OF USE THEREOF - A power system is provided which includes hydrogen production via reformation of gaseous or liquid hydrocarbons and/or alcohol feedstocks, in combination with high temperature PEM fuel cells which function as a power source, particularly for beverage and/or water cooler appliances, refrigerators or freezers and methods of use thereof. | 04-12-2012 |
Nora Iluri, Weston, MA US
Patent application number | Description | Published |
---|---|---|
20110208182 | PORTABLE RADIOFREQUENCY HYPERTHERMIA DEVICE WITH FLEXIBLE TREATMENT ELECTRODE FOR ELECTRIC FIELD CAPACITIVE COUPLED ENERGY TRANSFER - The present disclosure relates to a portable radiofrequency (RF) hyperthermia device having flexible applicator treatment electrodes for electric field capacitive coupled energy transfer, the device being useful for increasing the delivery of a systemically delivered drug at a localised target site. The portable RF device is suitable for use by a patient in their own home and the flexible applicator is a flexible, porous, light and easy to manipulate treatment electrode. The inventive device requires no specialist operator to ensure correct usage. | 08-25-2011 |
20120065714 | RADIOFREQUENCY HYPERTHERMIA DEVICE WITH TARGET FEEDBACK SIGNAL MODULATION - The present invention relates to a radiofrequency (RF) hyperthermia device for capacitive coupling comprising a radiofrequency source, an amplifier, a sensor, a feedback amplifier and a modulation signal generator, wherein the radiofrequency source produces a source signal which is modulated by the modulation signal generator, amplified by the amplifier and directed to a target, the sensor receives a feed back signal from the target that is directed to the feed back amplifier, wherein the feedback signal is amplified by the feedback amplifier and modulates the source signal to generate a target modified signal. This radiofrequency (RF) hyperthermia device is designed for increasing the selectivity of the hyperthermia treatment. | 03-15-2012 |
Nora Iluri, Los Gatos, CA US
Patent application number | Description | Published |
---|---|---|
20150217099 | TUMOR VACCINATION - The present invention relates to a vaccine composed of at least one immune stimulant and radiofrequency waves using capacitive coupling and to a method, especially an in-situ and in vivo vaccination method for treatment of primary cancer and its metastases even in disseminated cell-states, which cannot be detected by presently available imaging methods or for prevention of relapse of the cancer disease, and especially for enabling and supporting the patient's own immune system to recognize and kill the cancer cells and to build up a memory to prevent relapse of a cancer disease. | 08-06-2015 |
20150217124 | RF HYPERTHERMIA DEVICE FOR PERSONALIZED TREATMENT AND DIAGNOSIS - The present invention relates to a radiofrequency (RF) hyperthermia device for personalized treatment and diagnosis using capacitive coupling and without dipole antenna comprising a radiofrequency source, an amplifier, a sensor and a modulation signal input/generator, wherein the radiofrequency source produces a source signal which is modulated by the modulation signal input/generator using the phase information generated by homeostasis of the target to generate a modulated source signal, the modulated source signal is amplified by the amplifier and directed to a target, and the sensor detects the phase information generated by homeostasis of the target to provide a feedback signal, wherein the feedback signal modulates the source signal to generate a personalized modulated signal. This radiofrequency (RF) hyperthermia device is designed for personalized treatment and diagnosis of a target such as a patient or a malignant or tumorous area within a patient. | 08-06-2015 |
Nora Isomaki, Espoo FI
Patent application number | Description | Published |
---|---|---|
20130009264 | MOISTURE BARRIER - A moisture barrier, device or product having a moisture barrier or a method of fabricating a moisture barrier having at least a polymer layer, and interfacial layer, and a barrier layer. The polymer layer may be fabricated from any suitable polymer including, but not limited to, fluoropolymers such as polyethylene terephthalate (PET) or polyethylene naphthalate (PEN), or ethylene-tetrafluoroethylene (ETFE). The interfacial layer may be formed by atomic layer deposition (ALD). In embodiments featuring an ALD interfacial layer, the deposited interfacial substance may be, but is not limited to, Al | 01-10-2013 |
Nora Isomäki, Espoo FI
Patent application number | Description | Published |
---|---|---|
20120177903 | MULTILAYER COATING, METHOD FOR FABRICATING A MULTILAYER COATING, AND USES FOR THE SAME - A multilayer coating and a method for fabricating a multilayer coating on a substrate ( | 07-12-2012 |
Nora Kaarela, Helsinki FI
Patent application number | Description | Published |
---|---|---|
20150208918 | Device for Imaging an Eye - A device is for imaging an eye and is wearable on the object to be examined or otherwise able to be placed to the front of an eye or eyes. When the device is switched on, it automatically performs the imaging such that all images are useful. The device comprises a camera arrangement with optics and a camera sensor, and an illumination arrangement. The device comprises a control arrangement that switches the camera arrangement to take automatically one or more images of the eye, when the device is in front of the eye. The device comprises an image analysing arrangement or a connection to an image analysing arrangement that is provided for detecting a reflection in the image taken by the camera arrangement or in the image area of the camera arrangement and for transmitting the information about the detected reflection to the control arrangement which is provided thereby to repeat or decline imaging. When repeating the imaging the control arrangement alters the parameters of imaging. | 07-30-2015 |
20150208919 | Gaze Guidance Arrangement - A gaze guidance arrangement is formed in a device for imaging an eye, the device being wearable on the object to be examined or otherwise placeable to the front of an eye or eyes. The device comprises one or more camera arrangements and an illumination arrangement. The gaze guidance arrangement comprises a visual target, to which the gaze is supposed to be directed, in order to reach the desired position of the eye, and a control arrangement that guides the gaze guidance arrangement. The control arrangement is at least partly located in said device and further guides the imaging process of the device and the device takes images automatically when the eye is in a predetermined position to which the visual target has directed said eye. The gaze guidance arrangement comprises one or more target formation arrangements that is provided to form a visual target, the location of which in respect of the eye or the viewing direction of the eye or to both can be changed, and the location of the visual target is determined such that as the eye is directed to it or in its direction, it is in said predetermined position. | 07-30-2015 |
Nora Khaldi, Dublin IE
Patent application number | Description | Published |
---|---|---|
20140148378 | ANTIBACTERIAL PEPTIDES - The present invention relates to antibacterial peptides and analogs thereof, e.g., originating from, derived from, isolated and/or purified from mammalian milk, that reduce, inhibit and/or prevent the growth or proliferation of a bacterial organism. | 05-29-2014 |
Nora Kosztolanyi, Beaverton, OR US
Patent application number | Description | Published |
---|---|---|
20100086475 | Apparatus and Method of Making Transformed Water - The present invention provides an apparatus and method of producing transformed water without contact between the original transformed water and the water to be transformed. This is accomplished by organizing the original transformed water into a geometric contained arrangement such that a central cavity is created that substantially surrounds the water that is to be transformed. The water to be transformed is placed into a confined vessel such as a cylindrical container or a pipe inside the central cavity for about sixty seconds. This water then becomes transformed in the same likeness of the molecular clustering of the original transformed water. | 04-08-2010 |
20100186287 | Fuel Apparatus and Method - An apparatus and method of enhancing fuel combustion by organizing an amount of transformed water with a high level of stored energy into a geometric arrangement such that a central cavity is created that substantially surrounds a segment of a fuel line leading to a combustion device such as an internal combustion engine. The fuel passes within the space surrounded by the transformed water and becomes imprinted with a molecular clustering as a result of water memory transfer at a lower level of stored energy. This process alter the properties of the fuel allowing it to be utilized with a higher level of efficiency and with lower emissions of pollutants such as hydrocarbons and carbon monoxide. | 07-29-2010 |
Nora Lang, Bernhardstrasse 4 DE
Patent application number | Description | Published |
---|---|---|
20140348896 | Hydrophobic Tissue Adhesives - Pre-polymers for use as tissue sealants and adhesives, and methods of making and using thereof are provided. The pre-polymers have flow characteristics such that they can be applied through a syringe or catheter but are sufficiently viscous to remain in place at the site of application and not run off the tissue. The pre-polymers are also sufficiently hydrophobic to resist washout by bodily fluids. The pre-polymers are stable in bodily fluids; that is the pre-polymer does not spontaneously crosslink in bodily fluids absent the presence of an intentionally applied stimulus to initiate crosslinking. Upon crosslinking, the adhesive exhibits significant adhesive strength in the presence of blood and other bodily fluids. The adhesive is sufficiently elastic that it is able to resist movement of the underlying tissue. The adhesive can provide a hemostatic seal. The adhesive is biodegradable and biocompatible, causing minimal inflammatory response. | 11-27-2014 |
Nora Laryea, Saarbruecken DE
Patent application number | Description | Published |
---|---|---|
20090326146 | Silane coating material and a process to preduce silane coating - The invention relates to a silane coating material and a process to produce silane coating. | 12-31-2009 |
20100092686 | METHOD FOR THE PRODUCTION OF A COATING MATERIAL - The invention relates to a method for producing a coating material as well as the use of the coating material. | 04-15-2010 |
20110082254 | METHOD FOR THE PRODUCTION OF A HIGHLY ABRASION-RESISTANT VEHICLE PAINT, VEHICLE PAINT, AND THE USE THEREOF - The invention relates to a method for the production of a highly abrasion-resistant vehicle paint, vehicle paint, and the use thereof. | 04-07-2011 |
20120029143 | SILANE COATING MATERIAL AND A PROCESS TO PRODUCE SILANE COATING - A process to produce a silane coating includes charging one or several silanes, which are not or only minimally pre-condensed, with a reactant and the thus created coating material is applied onto a substrate and then hardened. Surprisingly it has been shown that, through the reaction involving higher-molecular and only slightly pre-cross-linked silanes with a suitable reactant, a new class of coating materials can be created. The approach is advantageous insofar as restrictions with respect to pot time no longer exist and, in addition, better features of the coating material are obtained, especially a high scratch-resistance. | 02-02-2012 |
Nora Ligorano, Brooklyn, NY US
Patent application number | Description | Published |
---|---|---|
20130010004 | FIBER OPTIC TAPESTRY - A woven fiber optic tapestry for conveying a specific representation of data on a woven fiber optic threaded surface. The tapestry is provided in a particular system including fiber optic threads threadedly arranged together to form a woven fiber optic panel, in which each of the threads is operatively connected to a light source, and a data interpretation device operatively connected to the light sources so as to provide a transfer of a pre-assigned value of data from the data interpretation device to the light sources and the threads, the transfer of the pre-assigned value causing an illumination of the light sources so as to correlate to a specific representation of the data. | 01-10-2013 |
Nora Luniak, Saarbrucken DE
Patent application number | Description | Published |
---|---|---|
20100272659 | RECOMBINANT PREPARATION OF SELECTED BROMELAIN FRACTIONS - The present invention pertains in general to Bromelain and particularly to the different active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed cysteine proteases, which are found in Bromelain. It has been found that the method for expression of the recombinant proteins is superior to the purification from Bromelain itself. | 10-28-2010 |
20110200541 | RECOMBINANT PREPARATION OF BROMELAIN INHIBITORS AND BROMELAIN INHIBITOR PRECURSOR - The present invention pertains in general to Bromelain and particularly to the active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed Bromelain inhibitor precursor and Bromelain inhibitors, which are found in Bromelain. It has been found that the recombinant expressed inhibitors have superior effects in terms of treatment of disorders and conditions than Bromelain or its protein fractions from plant extracts. | 08-18-2011 |
Nora Mardirosian, Bellemont, AZ US
Patent application number | Description | Published |
---|---|---|
20110064781 | NOVEL HEPARIN ENTITIES AND METHODS OF USE - The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive. | 03-17-2011 |
Nora Martínez Villanueva, Santiago De Compostela ES
Nora Martínez Villanueva, Santiago De Compostela ES
Nora Mineva, Brighton, MA US
Patent application number | Description | Published |
---|---|---|
20160130365 | Methods and compositions for prognosis, diagnosis, and treatment of ADAM8-expressing cancer - The transmembrane metalloproteinase-disintegrin ADAM8 mediates cell adhesion and shedding of ligands, receptors, and extracellular matrix components. ADAM8 is abundantly expressed in breast tumors and derived metastases compared to normal tissue, especially in triple-negative breast cancers (TNBCs). High ADAM8 levels predicted poor patient outcome, and ADAM8 promoted an aggressive phenotype of TNBC cells in culture. Tumors derived from TNBC cells with ADAM8 knockdown failed to grow beyond a palpable size and displayed poor vascularization. Circulating tumor cells and brain metastases were also significantly reduced. ADAM8 stimulated angiogenesis through release of VEGF-A and cell migration through β1-integrin activation. Treatment with anti-ADAM8 antibody in vivo resulted in reduced primary tumor burden and reduced metastases. Furthermore, antibody treatment of established tumors profoundly decreased metastases in a resection model. ADAM8 represents a promising novel target for treatment of TNBCs, which currently lack targeted therapies and frequently progress with fatal dissemination. | 05-12-2016 |
Nora Pan, Summertown Oxford GB
Patent application number | Description | Published |
---|---|---|
20140085297 | PLACEMENT OF INFORMATION FIELDS WHEN DISPLAYING A DIGITAL MEDICAL DATASET - A method is disclosed for displaying a digital medical image dataset. In an embodiment of the method, when a new set of diagnostic findings is generated, an associated new information field is also generated. A number of possible positions are determined for the new information field. Each of the positions is assigned an evaluation metric in accordance with a number of predefined criteria. The new information field is in this case arranged at that position having the best evaluation metric. Each existing information field that overlaps with the new information field is shifted until the existing information field is arranged free of overlap with the new information field. Other existing information fields that overlap with previously shifted information fields are shifted until all of the information fields are arranged free of overlap with one another. | 03-27-2014 |
Nora Pencheva, New York, NY US
Patent application number | Description | Published |
---|---|---|
20150023955 | Treatment and Diagnosis of Melanoma - The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods. | 01-22-2015 |
20150073053 | TREATMENT OF DRUG RESISTANT CANCER - The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods. | 03-12-2015 |
Nora Tarcic, Modiin IL
Patent application number | Description | Published |
---|---|---|
20100322900 | Treatment of multiple sclerosis with laquinimod - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 12-23-2010 |
20110027219 | Treatment of Crohn's disease with laquinimod - This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease. | 02-03-2011 |
20110217295 | TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis. | 09-08-2011 |
20110218179 | TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. | 09-08-2011 |
20110218203 | TREATMENT OF RHEUMATOID ARTHRITIS WITH A COMBINATION OF LAQUINIMOD AND METHOTREXATE - This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis. This invention also provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis. | 09-08-2011 |
20120142730 | USE OF LAQUINIMOD FOR REDUCING FATIGUE, IMPROVING FUNCTIONAL STATUS, AND IMPROVING QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS - The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis human patient, comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a method for providing neuroprotection to a human subject, the method comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof. | 06-07-2012 |
20130028866 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND INTERFERON-BETA - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-β. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-β for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-β in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-β in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 01-31-2013 |
20130029916 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with glatiramer acetate. This invention also provides a package and a pharmaceutical composition comprising laquinimod and glatiramer acetate for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with glatiramer acetate in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and glatiramer acetate in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 01-31-2013 |
20130096158 | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Fingolimod - This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 04-18-2013 |
20130184310 | TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis. | 07-18-2013 |
20130203807 | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY - This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day. | 08-08-2013 |
20130272996 | TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 10-17-2013 |
20130324574 | TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD - Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway. This application also provides a method for treating a subject suffering from an autoimmune disease-associated ocular inflammation comprising periodic ocular administration to the subject a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt, and an ocular pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating an autoimmune disease-associated ocular inflammation. | 12-05-2013 |
20140017226 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE - This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject fampridine as an add-on therapy to or in combination with laquinimod. This invention also provides a package comprising laquinimod and fampridine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides fampridine for use as an add-on therapy or in combination with laquinimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and fampridine for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fampridine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 01-16-2014 |
20140057883 | TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD - This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease. | 02-27-2014 |
20140105850 | TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 04-17-2014 |
20140200243 | TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD - This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease. | 07-17-2014 |
20140235670 | TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject. This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a progressive form of multiple sclerosis. | 08-21-2014 |
20150037263 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FINGOLIMOD - This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 02-05-2015 |
20150038508 | TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. | 02-05-2015 |
20150056281 | Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-β. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-β for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-β in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-β in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 02-26-2015 |
20150086549 | TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis. | 03-26-2015 |
20150359788 | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY - This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day. | 12-17-2015 |
20160038532 | Treatment of Multiple Sclerosis With Combination of Laquinimod and Glatiramer Acetate - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod an add-on therapy to or in combination with glatiramer acetate. This invention also provides a package and a pharmaceutical composition comprising laquinimod and glatiramer acetate for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with glatiramer acetate in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and glatiramer acetate in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 02-11-2016 |
20160082001 | TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 03-24-2016 |
Nora Torres-Nagel, Habach DE
Patent application number | Description | Published |
---|---|---|
20110143372 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue. | 06-16-2011 |
20110165592 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue. | 07-07-2011 |
20120122120 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor. | 05-17-2012 |
Nora Ventosa Rul, Bellaterra ES
Patent application number | Description | Published |
---|---|---|
20120004308 | METHOD FOR OBTAINING SOLID MICRO- OR NANOPARTICLES - The invention provides a novel method for obtaining solid micro- or nanoparticles with a homogeneous structure. A method is provided for obtaining solid micro- or nanoparticles with a homogeneous structure having a particle size of less than 10 μm where the processed solid compound has the natural, crystalline, amorphous, polymorphic and other features associated with the starting compound. In accordance with the invention a method which also makes it possible to obtain solid micro- or nanoparticles with a substantially spheroidal morphology is provided. | 01-05-2012 |
Nora Volkow, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20150209449 | INTRALIPID AS A CONTRAST AGENT TO ENHANCE SUBSURFACE BLOOD FLOW IMAGING - The present invention provides a method of imaging blood vessels or blood flow in blood vessels in an animal comprising: | 07-30-2015 |
Nora Wilke Nee Petersen, Kropp DE
Patent application number | Description | Published |
---|---|---|
20160031254 | Composition For Developing A Visually Discernible Colour And Corresponding Heat-Sensitive Recording Material - The present invention is directed to (i) a composition for forming a visually discernible color, (ii) the use of this composition for producing a heat-sensitive recording material, (iii) the corresponding heat-sensitive recording material comprising a substrate and this composition, and (iv) a process for producing the heat-sensitive recording material. | 02-04-2016 |
Nora Zidane, Paris FR
Patent application number | Description | Published |
---|---|---|
20120208176 | Multivalent Epitope in Complex with a Detection Marker for the Early Serodiagnosis of Infections - The present invention relates to a new method to determine the presence of antibodies to a pathogen in a serological sample using a new detection reagent which comprises at least two and preferably at least four copies of an antigen from the pathogen and a detectable marker. The present invention also relates to a new detection reagent which consists of at least two and preferably at least four antigenic peptides in a complex with a detectable marker via interacting multimerization domains upon both the antigenic peptides and detectable marker. | 08-16-2012 |
Nora Zulick, Albuquerque, NM US
Patent application number | Description | Published |
---|---|---|
20140297537 | AUTOMATED APPLICATION PROGRAMMING INTERFACE (API) SYSTEM AND METHOD - A method for leveraging email to complete an online transaction from a third party vendor, the method comprising: storing customer information, the customer information including a customer name, customer email address, customer shipping address, and customer billing information. The method further comprises receiving an authorization request from an application programming interface associated with a third party vendor requesting access to a portion of the customer information and receiving confirmation from a customer to allow the third party vendor to access the portion of the customer information. The method further comprising transmitting an access code to the third party vendor and receiving a request message from the third party vendor, wherein the request message comprises the access code, and wherein the request message requests an authorization token. The method may further comprise confirming the received access code and transmitting an authorization token to the third party vendor. | 10-02-2014 |
20150235210 | SYSTEM AND METHOD FOR DUAL EMAIL AND WEB BASED CHECKOUT IN AN UNSEGMENTED LIST - A system and method for leveraging email to complete a checkout for registered and unregistered customers of the e-commerce system are disclosed. The system and method include receiving, by an email payment gateway, an email message comprising a customer email address and a token. The token includes transaction information for a transaction from a third party vendor. The system and method further include determining a registration status of a customer based on the customer email address, wherein the registration status is one of a registered customer of the e-commerce system or an unregistered customer of the e-commerce system. The system and method further include decoding the token and sending an email message to the customer email address based on the registration status and the decoded token. | 08-20-2015 |